A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma.

Trial Profile

A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2013

At a glance

  • Drugs Ipilimumab (Primary) ; XL 281 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 29 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Aug 2011 Planned End Date changed from 1 Jun 2013 to 1 Mar 2013, as reported by ClinicalTrials.gov.
    • 28 Apr 2011 Planned End Date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top